Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.81 |
| ▸ | CHUK | O15111 | 9/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CIT | O14578 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 10/20 | 0.50 |
| ▸ | CDK9 | P50750 | 10/20 | 0.50 |
| ▸ | CASP7 | P55210 | 10/20 | 0.50 |
| ▸ | CDK1 | P06493 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | CDK7 | P50613 | 3/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986437 | 1.00 | IKBKB (0.81) | IKBKBCHUKCYP2C9CITCASP3 | |
| SCHEMBL3411545 | 0.89 | IKBKB (1.00) | IKBKBCHUKCYP2C9CITCASP3 | |
| SCHEMBL4891932 | 0.89 | IKBKB (1.00) | IKBKBCHUKCYP2C9CITCASP3 | |
| SCHEMBL2981857 | 0.89 | IKBKB (0.64) | IKBKBCHUKCYP2C9CITCASP3 | |
| SCHEMBL2988667 | 0.86 | IKBKB (0.60) | IKBKBCHUKCYP2C9CITCASP3 | |
| SCHEMBL2990386 | 0.85 | IKBKB (0.59) | IKBKBCHUKCIT | |
| SCHEMBL2996325 | 0.85 | IKBKB (0.59) | IKBKBCHUKCIT | |
| SCHEMBL2991821 | 0.85 | IKBKB (0.61) | IKBKBCHUKCYP2C9CITCASP3 | |
| SCHEMBL2985428 | 0.85 | IKBKB (0.61) | IKBKBCHUKCYP2C9CITCASP3 | |
| SCHEMBL2990321 | 0.83 | IKBKB (0.62) | IKBKBCHUKCYP2C9CITCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | claimed |
| EP-2162455-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | Glaxo Group Limited (GB) | 2010-03-17 | — | — | EP | claimed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | claimed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | IKBKB 11/4885CHUK 22/4885CYP2C9 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.